Literature DB >> 29299458

Antiangiogenic therapy and immune checkpoint blockade go hand in hand.

Luis Felipe Campesato1, Taha Merghoub1.   

Abstract

Year:  2017        PMID: 29299458      PMCID: PMC5750272          DOI: 10.21037/atm.2017.10.12

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  25 in total

1.  Cutting edge: proangiogenic properties of alternatively activated dendritic cells.

Authors:  Elena Riboldi; Tiziana Musso; Emanuela Moroni; Chiara Urbinati; Sergio Bernasconi; Marco Rusnati; Luciano Adorini; Marco Presta; Silvano Sozzani
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

2.  Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

Authors:  Elizabeth Allen; Arnaud Jabouille; Lee B Rivera; Inge Lodewijckx; Rindert Missiaen; Veronica Steri; Kevin Feyen; Jaime Tawney; Douglas Hanahan; Iacovos P Michael; Gabriele Bergers
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

Review 3.  Immunoregulation by tumor necrosis factor superfamily member LIGHT.

Authors:  Yugang Wang; Mingzhao Zhu; Mendy Miller; Yang-Xin Fu
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 4.  HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes.

Authors:  Jean-Philippe Girard; Christine Moussion; Reinhold Förster
Journal:  Nat Rev Immunol       Date:  2012-09-28       Impact factor: 53.106

5.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-04-26       Impact factor: 66.675

6.  Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion.

Authors:  Xiaoyuan Huang; Xiangyang Bai; Yang Cao; Jingyi Wu; Mei Huang; Duozhuang Tang; Si Tao; Tao Zhu; Yanling Liu; Yang Yang; Xiaoxi Zhou; Yanxia Zhao; Mingfu Wu; Juncheng Wei; Daowen Wang; Gang Xu; Shixuan Wang; Ding Ma; Jianfeng Zhou
Journal:  J Exp Med       Date:  2010-02-22       Impact factor: 14.307

7.  Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

Authors:  Olivier De Henau; Matthew Rausch; David Winkler; Luis Felipe Campesato; Cailian Liu; Daniel Hirschhorn Cymerman; Sadna Budhu; Arnab Ghosh; Melissa Pink; Jeremy Tchaicha; Mark Douglas; Thomas Tibbitts; Sujata Sharma; Jennifer Proctor; Nicole Kosmider; Kerry White; Howard Stern; John Soglia; Julian Adams; Vito J Palombella; Karen McGovern; Jeffery L Kutok; Jedd D Wolchok; Taha Merghoub
Journal:  Nature       Date:  2016-11-09       Impact factor: 49.962

8.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

Authors:  Farbod Shojaei; Xiumin Wu; Ajay K Malik; Cuiling Zhong; Megan E Baldwin; Stefanie Schanz; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  Nat Biotechnol       Date:  2007-07-29       Impact factor: 54.908

9.  Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.

Authors:  Rainer Riesenberg; Christoph Weiler; Oliver Spring; Martin Eder; Alexander Buchner; Tanja Popp; Mirna Castro; Robert Kammerer; Osamu Takikawa; Rudolf A Hatz; Christian G Stief; Alfons Hofstetter; Wolfgang Zimmermann
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

Review 10.  Why are tumour blood vessels abnormal and why is it important to know?

Authors:  J A Nagy; S-H Chang; A M Dvorak; H F Dvorak
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

View more
  11 in total

Review 1.  Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis.

Authors:  Massimiliano Mazzone; Gabriele Bergers
Journal:  Annu Rev Physiol       Date:  2019-02-10       Impact factor: 19.318

Review 2.  Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.

Authors:  Sun Ha Choi; Seung Soo Yoo; Shin Yup Lee; Jae Yong Park
Journal:  Arch Pharm Res       Date:  2022-04-21       Impact factor: 4.946

Review 3.  Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies.

Authors:  Dongxu Wang; Jianzhen Lin; Xu Yang; Junyu Long; Yi Bai; Xiaobo Yang; Yilei Mao; Xinting Sang; Samuel Seery; Haitao Zhao
Journal:  J Hematol Oncol       Date:  2019-04-24       Impact factor: 17.388

4.  The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).

Authors:  Brian I Rini; Dena Battle; Robert A Figlin; Daniel J George; Hans Hammers; Tom Hutson; Eric Jonasch; Richard W Joseph; David F McDermott; Robert J Motzer; Sumanta K Pal; Allan J Pantuck; David I Quinn; Virginia Seery; Martin H Voss; Christopher G Wood; Laura S Wood; Michael B Atkins
Journal:  J Immunother Cancer       Date:  2019-12-20       Impact factor: 13.751

5.  Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.

Authors:  Jay S Wunder; Minji J Lee; Junghyun Nam; Beatrice Y Lau; Brendan C Dickson; Dushanthi Pinnaduwage; Shelley B Bull; Peter C Ferguson; Andrew Seto; Nalan Gokgoz; Irene L Andrulis
Journal:  Oncoimmunology       Date:  2020-03-18       Impact factor: 8.110

Review 6.  Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma.

Authors:  Saket Jain; Eric J Chalif; Manish K Aghi
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

7.  Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment.

Authors:  Liting Xue; Xingyuan Gao; Haoyu Zhang; Jianxing Tang; Qian Wang; Feng Li; Xinxin Li; Xiaohong Yu; Zhihong Lu; Yue Huang; Renhong Tang; Wenqing Yang
Journal:  BMC Cancer       Date:  2021-10-22       Impact factor: 4.430

8.  Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience.

Authors:  Dylan J Martini; T Anders Olsen; Subir Goyal; Yuan Liu; Sean T Evans; Emilie Elise Hitron; Greta Anne Russler; Lauren Yantorni; Sarah Caulfield; Jacqueline T Brown; Jamie M Goldman; Bassel Nazha; Bradley C Carthon; Wayne B Harris; Omer Kucuk; Viraj A Master; Mehmet Asim Bilen
Journal:  J Immunother Precis Oncol       Date:  2022-06-14

Review 9.  Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis.

Authors:  Mikio Mukai; Keiko Komori; Toru Oka
Journal:  J Atheroscler Thromb       Date:  2018-09-14       Impact factor: 4.928

10.  Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets.

Authors:  Luis F Campesato; Chien-Huan Weng; Taha Merghoub
Journal:  Ann Transl Med       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.